These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24047116)

  • 1. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab.
    Wagenseller AG; Shada A; D'Auria KM; Murphy C; Sun D; Molhoek KR; Papin JA; Dutta A; Slingluff CL
    J Transl Med; 2013 Sep; 11():218. PubMed ID: 24047116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).
    Slingluff CL; Petroni GR; Molhoek KR; Brautigan DL; Chianese-Bullock KA; Shada AL; Smolkin ME; Olson WC; Gaucher A; Chase CM; Grosh WW; Weiss GR; Wagenseller AG; Olszanski AJ; Martin L; Shea SM; Erdag G; Ram P; Gershenwald JE; Weber MJ
    Clin Cancer Res; 2013 Jul; 19(13):3611-20. PubMed ID: 23620404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
    Kim JH; Ahn JH; Lee M
    Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis.
    Tembe V; Schramm SJ; Stark MS; Patrick E; Jayaswal V; Tang YH; Barbour A; Hayward NK; Thompson JF; Scolyer RA; Yang YH; Mann GJ
    Pigment Cell Melanoma Res; 2015 May; 28(3):254-66. PubMed ID: 25490969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
    Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
    Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.
    Lindholm EM; Ragle Aure M; Haugen MH; Kleivi Sahlberg K; Kristensen VN; Nebdal D; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Mol Oncol; 2019 Oct; 13(10):2278-2296. PubMed ID: 31402562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
    Davies MA; Fox PS; Papadopoulos NE; Bedikian AY; Hwu WJ; Lazar AJ; Prieto VG; Culotta KS; Madden TL; Xu Q; Huang S; Deng W; Ng CS; Gupta S; Liu W; Dancey JE; Wright JJ; Bassett RL; Hwu P; Kim KB
    Clin Cancer Res; 2012 Feb; 18(4):1120-8. PubMed ID: 22223528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput miRNA profiling of human melanoma blood samples.
    Leidinger P; Keller A; Borries A; Reichrath J; Rass K; Jager SU; Lenhof HP; Meese E
    BMC Cancer; 2010 Jun; 10():262. PubMed ID: 20529253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
    Niessner H; Kosnopfel C; Sinnberg T; Beck D; Krieg K; Wanke I; Lasithiotakis K; Bonin M; Garbe C; Meier F
    Exp Dermatol; 2017 Jul; 26(7):598-606. PubMed ID: 28423208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
    Stark MS; Bonazzi VF; Boyle GM; Palmer JM; Symmons J; Lanagan CM; Schmidt CW; Herington AC; Ballotti R; Pollock PM; Hayward NK
    Oncotarget; 2015 Jul; 6(19):17753-63. PubMed ID: 25980496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
    Flaherty KT; Manola JB; Pins M; McDermott DF; Atkins MB; Dutcher JJ; George DJ; Margolin KA; DiPaola RS
    J Clin Oncol; 2015 Jul; 33(21):2384-91. PubMed ID: 26077237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
    Subbiah V; Westin SN; Wang K; Araujo D; Wang WL; Miller VA; Ross JS; Stephens PJ; Palmer GA; Ali SM
    J Hematol Oncol; 2014 Jan; 7():8. PubMed ID: 24422672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of microRNAs in melanoma.
    Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
    Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
    Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
    Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
    Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.